EPHA3 is recurrently mutated in adenocarcinoma [62], [63] and has been implicated in renal carcinoma, glioblastoma, colorectal, breast and lung cancer [63], [64], [65], [66], [67]. Here, EPHA3 is linked to lung carcinoma.